161117-83-5

Basic information

• Product Name: tert-butyl 2-methoxypyridin-3-ylcarbamate
• Synonyms: tert-butyl 2-methoxypyridin-3-ylcarbamate;3-(N-tert-butoxycarbonylaMino)-2-Methoxypyridine;CarbaMic acid, (2-Methoxy-3-pyridinyl)-, 1,1-diMethylethyl ester
• CAS NO: 161117-83-5
• Molecular Formula: C₁₁H₁₆N₂O₃
• Molecular Weight: 224.26
• Mol File: 161117-83-5.mol

Chemical Properties

• Boiling Point: 276.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.146±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.31±0.70(Predicted)
• CAS DataBase Reference: tert-butyl 2-methoxypyridin-3-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-methoxypyridin-3-ylcarbamate(161117-83-5)
• EPA Substance Registry System: tert-butyl 2-methoxypyridin-3-ylcarbamate(161117-83-5)

Safety Data

• Hazardous Substances Data: 161117-83-5(Hazardous Substances Data)

Usage

Uses

Used in Research and Development:
Tert-butyl 2-methoxypyridin-3-ylcarbamate is used as a chemical precursor for the synthesis of other compounds in research and development. Its unique structure allows for potential applications in the creation of new chemical entities with specific properties and functions.
Used in Chemical Reactions:
In the chemical industry, tert-butyl 2-methoxypyridin-3-ylcarbamate is used as a reactant in specific chemical reactions. Its complex structure and functional groups enable it to participate in various reactions, leading to the formation of new compounds with desired characteristics.
Used in Pharmaceutical Industry:
Tert-butyl 2-methoxypyridin-3-ylcarbamate is used as a potential candidate for drug development. Its unique structure and functional groups may contribute to the design of new pharmaceutical compounds with therapeutic applications.
Used in Material Science:
In the field of material science, tert-butyl 2-methoxypyridin-3-ylcarbamate is used as a component in the synthesis of new materials with specific properties. Its incorporation into materials may lead to the development of advanced materials with applications in various industries.

InChI:InChI=1S/C11H16N2O3/c1-11(2,3)16-10(14)13-8-6-5-7-12-9(8)15-4/h5-7H,1-4H3,(H,13,14)

Upstream product

• 20265-38-7 3-amino-2-methoxypyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 24608-52-4 tert-butyl chloroformate 

Downstream Products

• 162709-18-4 2-Methoxy-4-(phenylmethyl)-3-pyridinecarbamic acid 1,1-dimethylethyl ester 
• 684-16-2 Hexafluoroacetone 
• 162709-22-0 4-Formyl-2-methoxy-3-pyridinecarbamic acid 1,1-dimethylethyl ester 
• 1338219-65-0 7-chloro-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine 
• 1338219-67-2 2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-7-yl(phenyl)methanone 
• 162709-20-8 4-Iodo-2-methoxy-3-pyridinecarbamic acid 1,1-dimethylethyl ester 
• 175965-74-9 4-fluoro-2-methoxypyridin-3-amine 

Relevant articles and documents

Synthesis method of 8-chloro-1, 7-naphthyridine-3-formaldehyde

The invention discloses a synthesis method of 8-chloro-1, 7-naphthyridine-3-formaldehyde, which comprises the following synthesis steps: 1) taking a compound I 2-methoxy-3-aminopyridine as an initialraw material, protecting amino to obtain a compound II; 2) reacting the compound II with an hydroformylation reagent under an alkaline condition to obtain a compound III; 3) deprotecting the compoundIII under an acidic condition to obtain a compound IV or a salt of the compound IV; 4) performing cyclization reaction on the compound IV and an acrylate compound under the action of a Lewis acid to prepare a compound V; 5) carrying out chlorination reaction on the compound V and a chlorination reagent to prepare a compound VI; and 6) dissolving the compound VI 8-chloro-1, 7-naphthyridine-3-formate as a raw material in a solvent, and reducing under the action of a reducing reagent to directly obtain 8-chloro-1, 7-naphthyridine-3-formaldehyde, namely a compound VII. The preparation method disclosed by the invention has the characteristics of suitability for industrial production, relatively low cost and simple operation.

Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors

A highly ligand efficient, novel 8-oxo-pyridopyrimidine containing inhibitor of Jak1 and Jak2 isoforms with a pyridone moiety as the hinge-binding motif was discovered. Structure-based design strategies were applied to significantly improve enzyme potency and the polarity of the molecule was adjusted to gain cellular activity. The crystal structures of two representative inhibitors bound to Jak1 were obtained to enable SAR exploration.

Preparation of azaindolines and benzoyl substituted azaindolines: Precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors

The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors.

Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists

Novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives were identified as potent human H3 receptor inverse agonists. After systematic modification of lead 5a, the potent and selective analog 5r was identified. Elimination of hERG K+ channel and human α1A-adrenoceptor activities is the main focus of the present study.

QUINAZOLINE DERIVATIVE

This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (II) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them

The present invention relates to the compounds of formula (I) in which X, R1, R2 and R3are as defined in claim 1. These compounds are cholesteryl acyl transferase (ACAT) inhibitors.

Synthesis of 6-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones via directed lithiation of 2-substituted 5-aminopyridine derivatives

Directed lithiation of Boc or pivaloyl derivatives of 2-substituted 5-aminopyridines with BuLi-TMEDA in diethyl ether at -10°C gave 4-lithio derivatives which were quenched with CO2 to give the analogous C-4 carboxylic acids. Hydrolysis of the protecting groups with either TFA or aqueous KOH gave 2-substituted 5-aminopyridine-4-carboxylic acids which were converted to 6-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones by reaction with formamide or, more optimally, formamidine acetate. Boc protected aminopyridines provided the best overall results, with synthesis of these derivatives best achieved by direct reaction of the aminopyridine with di-tert-butyl dicarbonate in the absence of added base.

Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones

A method for preparing certain 4-alkyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones, which employs the following reaction scheme: STR1

A Simple Method for the Protection of Aryl Amines as their t-Butylcarbamoyl (Boc) Derivatives

It has been found that aryl amines can be directly protected as their Boc derivatives by treatment of the amine with two equivalents of NaHMDS in THF followed by one equivalent of di-t-butyldicarbonate.This procedure works on a wide variety of both electron-rich and electron-deficient aryl amines.